Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats

Cardiovasc Res. 2014 Oct 1;104(1):5-14. doi: 10.1093/cvr/cvu176. Epub 2014 Jul 31.

Abstract

Aims: We investigated whether glucose fluctuations aggravate cardiac fibrosis and increase the occurrence of atrial fibrillation (AF) in rats with diabetes mellitus (DM).

Methods and results: Streptozotocin-induced diabetic rats were randomly divided into three groups: uncontrolled DM (U-STZ) group, controlled DM (C-STZ) group, and DM with glucose fluctuations (STZ-GF) group. Glucose fluctuations were induced by fasting for 24 h and additional regular insulin injections (0.5 IU/kg) administered three times per week for three consecutive weeks. C-STZ rats were administered long acting insulin (20 IU/kg) twice a day to control blood glucose levels. Cardiac fibrosis evaluated by Masson trichrome staining and the expressions of collagen type 1, collagen type 3, and α-smooth muscle actin were increased in U-STZ rats compared with C-STZ rats, which were more pronounced in STZ-GF rats. The inducibility of AF was significantly larger in U-STZ rats than C-STZ rats and was greatest in STZ-GF rats. To explore the mechanism of cardiac fibrosis, we investigated the levels of reactive oxygen species (ROS) and apoptosis. The expression of malondialdehyde, an indicator of ROS levels, was significantly upregulated in STZ-GF rats compared with U-STZ rats, along with increased thioredoxin-interacting protein (Txnip) expression in STZ-GF rats. Furthermore, caspase-3 expression and the number of TUNEL-positive cells were significantly increased in STZ-GF rats compared with U-STZ and C-STZ rats.

Conclusion: Glucose fluctuations increase the incidence of AF by promoting cardiac fibrosis. Increased ROS levels caused by upregulation of Txnip expression may be a mechanism whereby in glucose fluctuations induce fibrosis.

Keywords: Atrial fibrillation; Diabetes mellitus; Glucose fluctuation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Action Potentials
  • Animals
  • Apoptosis
  • Atrial Fibrillation / blood
  • Atrial Fibrillation / etiology*
  • Atrial Fibrillation / pathology
  • Atrial Fibrillation / physiopathology
  • Biomarkers / blood
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism*
  • Carrier Proteins / metabolism
  • Caspase 3 / metabolism
  • Cell Cycle Proteins
  • Cells, Cultured
  • Collagen Type I / metabolism
  • Collagen Type III / metabolism
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / complications*
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetic Cardiomyopathies / blood
  • Diabetic Cardiomyopathies / etiology*
  • Diabetic Cardiomyopathies / pathology
  • Diabetic Cardiomyopathies / physiopathology
  • Fibrosis
  • Hypoglycemic Agents / pharmacology
  • Insulin, Long-Acting / pharmacology
  • Male
  • Malondialdehyde / metabolism
  • Myocardium / metabolism*
  • Myocardium / pathology
  • Oxidative Stress
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism
  • Refractory Period, Electrophysiological
  • Signal Transduction
  • Time Factors
  • Ventricular Dysfunction, Left / etiology
  • Ventricular Dysfunction, Left / metabolism
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Function, Left

Substances

  • Actins
  • Biomarkers
  • Blood Glucose
  • Carrier Proteins
  • Cell Cycle Proteins
  • Collagen Type I
  • Collagen Type III
  • Hypoglycemic Agents
  • Insulin, Long-Acting
  • Reactive Oxygen Species
  • TXNIP protein, rat
  • smooth muscle actin, rat
  • Malondialdehyde
  • Casp3 protein, rat
  • Caspase 3